# LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

> **NCT00019435** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Bladder Cancer
- Breast Cancer
- Colorectal Cancer
- Esophageal Cancer
- Gastric Cancer
- Lung Cancer
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** LMB-9 immunotoxin

## Key facts

- **NCT ID:** NCT00019435
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2015-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00019435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00019435, "LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00019435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*